12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Deals

Intarcia, Quintiles deal

The partners finalized a deal under which the CRO will make an equity investment in Intarcia and conduct clinical trials for diabetes product ITCA 650. In October, the partners signed a letter of intent....

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >